ABB Robotics and the U.S. biotech Vyripharm Enterprises are collaborating to develop an automated laboratory testing platform. This will enable the quality control of raw material and novel pharmaceutical compounds and their certification.
ABB Robotics from Zurich and Vyripharm Enterprises with headquarters in Houston, Texas, in the USA, plan to develop a fully automated robotic platform that will be the first of its kind. According to a press release, the laboratory testing platform will enable the quality control of raw material and compounds for the pharmaceutical industry against established standards and deliver data for the certification of the tested samples.
“The rapid growth of the biopharma supply chain has produced a need for standardized testing,” explained John W. Shadle, Managing Director at Vyripharm. This will “assure that the methods and instrumentation used in the testing process produce equivalent results across different laboratories”.
Under the terms of the partnership, Vyripharm will provide process definition, intellectual property, equipment, software and associated funds. ABB will provide state-of-the-art automation software and robotics.
“ABB’s automated solutions will enhance process productivity and sample traceability,” said Dr José Collados, Line Manager for ABB Life Sciences and Healthcare Robotic Solutions. “When combined with Vyripharm’s process and software, this will improve productivity and optimize processes, substantively advancing the future of patient care.”
Two beta sites located in Texas and Colorado are currently under construction and are expected to be operational in 2023. Other locations are planned throughout the USA and internationally.